DELETION OF ARGININE (608) IN ACID SPHINGOMYELINASE IS THE PREVALENT MUTATION AMONG NIEMANN-PICK DISEASE TYPE-B PATIENTS FROM NORTHERN AFRICA

被引:48
作者
VANIER, MT
FERLINZ, K
ROUSSON, R
DUTHEL, S
LOUISOT, P
SANDHOFF, K
SUZUKI, K
机构
[1] CTR HOSP LYON SUD, FDN GILLET MERIEUX, F-69310 PIERRE BENITE, FRANCE
[2] INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY
[3] UNIV N CAROLINA, SCH MED, BRAIN & DEV RES CTR, CHAPEL HILL, NC 27599 USA
关键词
D O I
10.1007/BF01247328
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
There is a high incidence of Niemann-Pick type B disease in the Maghreb region of North Africa, which includes Morocco, Algeria and Tunisia. A hypothesis that there may well be a common, predominant mutant acid sphingomyelinase allele responsible for the type B phenotype in this population has been tested. A deletion of an arginine codon at amino acid residue 608 was found in one patient. The same mutation was also observed in another of our cases. An original screening procedure using 3'-end digoxigenin-labeled allele-specific oligonucleotides and chemiluminescent detection was developed and used parallel to, the conventional assay with 5'-end radiolabeled oligonucleotides. Of the 15 non-related, non-Jewish North African type B patients studied, 12 were homozygous and two compound heterozygous for this deletion (26 DELTAR608 alleles/30 mutant alleles). Among type B patients from other geographic regions (France, UK, Italy, Czechoslovakia), this mutation was observed in only one of the 16 alleles studied. Our results indicate that deletion of arginine 608 in the acid sphingomyelinase gene is the highly prevalent mutation underlying Niemann-Pick type B disease in the population of Maghreb. A varying severity of the clinical and enzymatic expression within the non-neuronopathic phenotype has however been observed in patients homozygous for the mutation.
引用
收藏
页码:325 / 330
页数:6
相关论文
共 31 条
[1]   IDENTIFICATION OF AN ALTERED SPLICE SITE IN ASHKENAZI TAY-SACHS DISEASE [J].
ARPAIA, E ;
DUMBRILLEROSS, A ;
MALER, T ;
NEOTE, K ;
TROPAK, M ;
TROXEL, C ;
STIRLING, JL ;
PITTS, JS ;
BAPAT, B ;
LAMHONWAH, AM ;
MAHURAN, DJ ;
SCHUSTER, SM ;
CLARKE, JTR ;
LOWDEN, JA ;
GRAVEL, RA .
NATURE, 1988, 333 (6168) :85-86
[2]  
Ausubel FM, 2003, CURRENT PROTOCOLS MO
[3]   METABOLISM OF SPHINGOMYELIN BY INTACT CULTURED FIBROBLASTS - DIFFERENTIATION OF NIEMANN-PICK DISEASE TYPE-A AND TYPE-B [J].
BEAUDET, AL ;
MANSCHRECK, AA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982, 105 (01) :14-19
[4]   GAUCHER DISEASE - NEW MOLECULAR APPROACHES TO DIAGNOSIS AND TREATMENT [J].
BEUTLER, E .
SCIENCE, 1992, 256 (5058) :794-799
[5]  
DOSSANTOS MR, 1991, AM J HUM GENET, V49, P886
[6]   A NEW VARIANT OF SPHINGOMYELINASE DEFICIENCY (NIEMANN-PICK) - VISCEROMEGALY, MINIMAL NEUROLOGICAL LESIONS AND LOW INVIVO DEGRADATION RATE OF SPHINGOMYELIN [J].
ELLEDER, M ;
NEVORAL, J ;
SPICAKOVA, V ;
HYNIOVA, H ;
KRAUS, J ;
KRASNY, J ;
VANIER, MT .
JOURNAL OF INHERITED METABOLIC DISEASE, 1986, 9 (04) :357-366
[7]   NIEMANN-PICK DISEASE (VARIATION IN THE SPHINGOMYELINASE DEFICIENT GROUP) - NEUROVISCERAL PHENOTYPE-(A) WITH AN ABNORMALLY PROTRACTED CLINICAL COURSE AND VARIABLE EXPRESSION OF NEUROLOGICAL SYMPTOMATOLOGY IN 3 SIBLINGS [J].
ELLEDER, M ;
CIHULA, J .
EUROPEAN JOURNAL OF PEDIATRICS, 1983, 140 (04) :323-328
[8]   MOLECULAR-BASIS OF ACID SPHINGOMYELINASE DEFICIENCY IN A PATIENT WITH NIEMANN-PICK DISEASE TYPE-A [J].
FERLINZ, K ;
HURWITZ, R ;
SANDHOFF, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1187-1191
[9]   SEVERE CHILDHOOD MUSCULAR-DYSTROPHY AFFECTING BOTH SEXES AND FREQUENT IN TUNISIA [J].
HAMIDA, MB ;
FARDEAU, M ;
ATTIA, N .
MUSCLE & NERVE, 1983, 6 (07) :469-480
[10]  
Kofman J, 1979, Poumon Coeur, V35, P217